With a Nod to Uncle Sam, Amgen Plans $300 Million Investment in U.S. Biomanufacturing Plant
SUGAR LAND--February 16, 2018--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--It is often tricky to prove cause and effect, but in the case of federal tax reform and Amgen, the correlation is quite clear. The Trump administration approved major corporate tax benefits, and now the company plans to construct a grassroot, $300 million biomanufacturing plant in the United States.
Within this article: Details on how Amgen and other pharma companies are plotting a return to U.S. shores.